2022, ' The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge ', The Lancet, vol. 399, no. 10330, pp. 1101-1103 . https://doi.org/10.1016/S0140-6736(22)00184-2
Meattini, I, Becherini, C, Boersma, L, Kaidar-Person, O, Marta, G N, Montero, A, Offersen, B V, Aznar, M C, Belka, C, Brunt, A M, Dicuonzo, S, Franco, P, Krause, M, MacKenzie, M, Marinko, T, Marrazzo, L, Ratosa, I, Scholten, A, Senkus, E, Stobart, H, Poortmans, P & Coles, C E 2022, ' European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer ', The Lancet Oncology, vol. 23, no. 1, pp. e21-e31 . https://doi.org/10.1016/S1470-2045(21)00539-8 The lancet oncology
Lancet (London, England) FAST-Forward Trial Management Group 2020, ' Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward) : 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial ', Lancet (London, England), vol. 395, no. 10237, pp. 1613-1626 . https://doi.org/10.1016/S0140-6736(20)30932-6